Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and...
-
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and...
-
PharmAla announces completion of onboarding for its US distribution centre and resignation of its Chief Operating Officer.
-
Psycan discloses troubling statistics showing that Health Canada has begun to deny numerous doctor requests for MDMA and Psilocybin
-
SAN JOSE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve...
-
PharmAla incorporates a new entity in Australia to take advantage of tax incentives, and appoints Dr. Evan Lewis to its clinical advisory board.
-
PharmAla delivers over 500 LaNeo MDMA capsules to Merhavim Psychiatric Hospital to be used in a clinical trial in exchange for IP rights to trial results
-
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the...
-
PharmAla releases Q3 financials showing increased customer deposit and SAP sales growth
-
Enhanced Virtual Trip platform goes live with improved user experience and first selection of PS2025 session videosConference drew 8,000+ attendees, more than $1 million donated, and 1,100+ recurring...